| Literature DB >> 31296482 |
Maria Helena de Magalhães Barbosa1, Maria Clara de Magalhães-Barbosa2, Jaqueline Rodrigues Robaina2, Arnaldo Prata-Barbosa3, Marco Antonio de Melo Tavares de Lima4, Antonio José Ledo Alves da Cunha5.
Abstract
INTRODUCTION: Possible associations between Zika virus infection and hearing loss were observed during the epidemic in the Americas.Entities:
Keywords: Distúrbios auditivos; Hearing disorders; Hearing loss; Infecção pelo Zika vírus; Perda de audição; Zika virus infection
Mesh:
Year: 2019 PMID: 31296482 PMCID: PMC9443055 DOI: 10.1016/j.bjorl.2019.05.002
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Figure 1Flow diagram with the selection stages of the studies. The 27 studies included in the review were split according to the presence of each of the outcomes studied (some studies addressed more than one outcome).
Quality evaluation of the case report or case series studies describing hearing impairment associated to Zika virus infection.
| Author, year | Title | Communication means | Study design | General quality | Hearing evaluation quality | |
|---|---|---|---|---|---|---|
| Acquired Zika infection | Tappe et al., 2015 | Acute Zika Virus Infection after Travel to Malaysian Borneo, September 2014 | Emerging Infectious Diseases | Case report | Low | Low |
| Martins et al., 2017 | Otological findings in patients following infection with Zika virus: case report | Audiology Communication Research | Case report | High | High | |
| Vinhaes et al., 2017 | Transient Hearing Loss in Adults Associated With Zika Virus Infection | Clinical Infectious Diseases: an official publication of the Infectious Disease Society of America | Case report | Moderate | Moderate | |
| Congenital Zika infection | Leal et al., 2016 | Sensorineural hearing loss in a case of congenital Zika virus | Brazilian Journal of Otorhinolaryngology | Case report | Moderate | Moderate |
| Leal et al., 2016 | Hearing Loss in Infants with Microcephaly and Evidence of Congenital Zika Virus Infection – Brazil, November 2015–May 2016 | MMWR. Morbidity and Mortality Weekly Report | Case series | Moderate | Moderate | |
| Microcephaly Epidemic Research Group, 2016 | Microcephaly in Infants, Pernambuco State, Brazil, 2015 | Emerging Infectious Diseases | Case series | Low | Low | |
| Van der Linden et al., 2016 | Description of 13 Infants Born During October 2015–January 2016 With Congenital Zika Virus Infection Without Microcephaly at Birth – Brazil | MMWR. Morbidity and Mortality Weekly Report | Case series | Moderate | Low | |
| Besnard et al., 2016 | Congenital cerebral malformations and dysfunction in fetuses and newborns following the 2013 to 2014 Zika virus epidemic in French Polynesia | Euro Surveillance | Case series | Low | Low | |
| Borja et al., 2017 | Hearing screening in children exposed to zika virus during pregnancy | Revista de Ciências Médicas e Biológicas | Case series | Low | Moderate | |
| Nogueira et al., 2017 | Adverse birth outcomes associated with Zika virus exposure during pregnancy in São José do Rio Preto, Brazil | Clinical Microbiology and Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases | Case series | Moderate | Low | |
| Satterfield-Nash et al., 2017 | Health and Development at Age 19–24 Months of 19 Children Who Were Born with Microcephaly and Laboratory Evidence of Congenital Zika Virus Infection During the 2015 Zika Virus Outbreak – Brazil, 2017 | MMWR. Morbidity and Mortality Weekly Report | Case series | Low | Low | |
| Silva et al., 2017 | Hearing screening in children exposed to Zika virus | Anals of II Brazilian Congress of Health Sciences | Case series | Low | Low | |
| Marques Abramov et al., 2018 | Auditory brainstem function in microcephaly related to Zika virus infection | Neurology | Case series | Moderate | Moderate | |
| Fandiño-Cárdenas et al., 2018 | Zika Virus Infection during Pregnancy and Sensorineural Hearing Loss among Children at 3 and 24 Months Post-Partum | Journal of Tropical Pediatrics | Case series | Low | Moderate | |
| Sanz Cortes et al., 2018 | Clinical Assessment and Brain Findings in a Cohort of Mothers, Fetuses and Infants Infected with Zika Virus | American Journal of Obstetrics and Gynecology | Case series | Moderate | Low | |
| Leite et al., 2018 | Hearing Screening in children with Congenital Zika Virus Syndrome in Fortaleza, Ceará, Brazil, 2016 | Epidemiologia e Serviços de Saúde | Case series | Moderate | Moderate | |
| Lage et al., 2019 | Clinical, Neuroimaging, and Neurophysiological Findings in Children with Microcephaly Related to Congenital Zika Virus Infection | International Journal of Environmental Research and Public Health | Case series | Moderate | Low | |
| Gely-Rojas et al., 2018 | Congenital Zika Syndrome in Puerto Rico, Beyond Microcephaly, A Multiorgan Approach | Puerto Rico Health Sciences Journal | Case series | Low | Low | |
| Calle-Giraldo et al., 2019 | Outcomes of Congenital Zika Virus Infection During an Outbreak in Valle del Cauca, Colombia | The Pediatric Infectious Disease Journal | Case series | Moderate | Low | |
| Julander et al., 2018 | Consequences of in utero exposure to Zika virus in offspring of AG129 mice | Scientific Reports | Non-randomized controlled trial (in animals) | Moderate | Moderate |
Scientific evidence for Auditory alterations related to Zika virus according to Grading of Recommendations Assessment, Development and Evaluation.
| Outcomes | No. of studies | No. of patients | Frequency of altered hearing assessments | Scientific evidence | Comments |
|---|---|---|---|---|---|
| Frequency of functional auditory changes related to ZIKV exposure | 15 | 515 (children) | OAE – 18.5% | Insufficient | Predominantly cases series |
| 1 case report and 14 case series | 244 OAE and 448 a-ABR | a-ABR – 15.2% | Great heterogeneity of study population |
OAE, Otoacoustic Emissions; a-ABR, automated Auditory Brainstem Response.
Characteristics of the studies on hearing impairment in cases of acquired Zika virus infection.
| Author, year | Country of origin | Sample | Age at hearing evaluation | ZIKV and other flavivirus testing | Hearing evaluation |
|---|---|---|---|---|---|
| Tappe et al., 2015 | Germany | 1 | 45 years | IgM ZIKV+ (day 6) | Not performed (hearing symptoms related) |
| IgG ZIKV+ (day 6) | |||||
| PRNT ZIKV+ (day 11) | |||||
| Martins et al., 2017 | Brazil | 2 | 41 and 49 years | IgG ZIKV+ | T-OAE, DP-OAE, ABR threshold-click |
| IgG DENV+ | Tonal and vocal audiometry with imitanciometry | ||||
| Vinhaes et al., 2017 | Brazil | 3 | 23, 54 and 58 years | IgM ZIKV e PRNT ZIKV+(3/3) | Audiometry |
| IgM DENV+(2/3) – cross-reaction? | |||||
| PRNT DENV+(1/3) – cross-reaction? |
ZIKV, Zika Virus; DENV, Dengue Virus; PRNT, Plaque Reduction Neutralization Test; IgG and IgM, G and M Immunoglobulins; T-OAE, Transient Otoacoustic Emissions; DP-OAE, Distortion Product Otoacoustic Emissions; ABR, Auditory Brainstem Response.
Characteristics of studies describing hearing evaluation in cases of congenital Zika virus infection.
| Author, year | Country of origin | Total sample ( | Microcephaly/neurologic changes ( | Lab ZIKV | Age at hearing evaluation | Hearing evaluation |
|---|---|---|---|---|---|---|
| Leal et al., 2016 | Brazil | 1 with microcephaly | 1 | Mother: ND | Newborn (age not specified) | 1/1 |
| Leal et al., 2016 | Brazil | 70 children with microcephaly and ZIKV+ (8 preterm) | 70 | Mother: ND | 1st test: 114 ± 59.1 d (mean ± SD); 97 d (16–315 d) median (range) | 5/70 (7.1%) |
| Microcephaly Epidemic Research Group, 2016 | Brazil | 104 children with microcephaly during the ZIKV epidemy (10 preterm) | 104 | Mother: ND | NI | OEA – 2/23 (8.7%) |
| Van der Linden et al., 2016 | Brazil | 13 children with ZIKV+ (2 preterm) | 0 at term | Mother: ND | NI | a-ABR – 0/11 (0%) |
| Besnard et al., 2016 | French Polynesian | 19 fetus e newborns with malformations and/or disfunctions probably caused by ZIKV (2 preterm and 11 termination of pregnancy) | 8 | Mother: 4/7 (PCR – amniotic fluid) | NI | 1/NI |
| Borja et al., 2017 | Brazil | 76 children with suspected congenital ZIKV infection (8 preterm) | 46 | Mother: ND | 101 ± 86 d (mean ± SD) | T-OAE |
| Nogueira et al., 2017 | Brazil | 54 children prenatally exposed to ZIKV (8 preterm) | 0 | Mother: 54/54 PCR [45/53 (blood); 41/52 (urine)] | NI | OAE – 6/34 (17.6%) |
| Satterfield-Nash et al., 2017 | Brazil | 19 children with microcephaly at term and laboratorial evidence of ZIKV infection | 19 | Mother: ND | 22 mo (19–24 mo) | 13/19 (68.4%) |
| Silva et al., 2017 | Brazil | 24 children with microcephaly and prenatally exposed to ZIKV | 24 | ND | 5 mo (1–12 mo) | T-OAE – 18/24 (75%) |
| Marques Abramov et al., 2018 | Brazil | 19 children with microcephaly and prenatally exposed to ZIKV | 19 | Mother: ND | 29.57 ± 17.84 wks (12–62 wks) | ABR (neurodiagnostic-click) – 3/19 (15.8%) |
| Fandiño-Cárdenas et al., 2018 | Colombia | 43 children born to mothers with epidemiologic criteria for ZIKV infection | 3 | Mother: 0/43 | 1st test: 3.5 mo (mean); | OAE/a-ABR/Tympanometry – 0/43 (0%) |
| Sanz Cortes et al., 2018 | Colombia | 12 children with CNS malformations exposed prenatally to ZIKV | 9 | Mother: 7/12 | NI | a-ABR – 0/2 (0%) |
| Leite et al., 2018 | Brazil | 45 children with CZS | 45 | Mother: ND | 10 mo (1–20 mo) | OAE – 13/43 – 11/43 RE (25.6%) (10 altered tympanometry) and 12/43 LE (27.9%) (9 altered tympanometry) |
| Lage et al., 2019 | Brazil | 102 children with microcephaly and gestational ZIKV clinical symptoms | 102 | Mother: ND | NI | ABR – 17.3% ( |
| Gely-Rojas et al., 2018 | Puerto Rico | 191 infants born to mothers with ZIKV positive test during pregnancy | 15 | Mother: 191/191 (PCR or IgM) | NI | ABR – 38/191 (20%) |
| Calle-Giraldo et al., 2019 | Colombia | 171 exposed fetuses (17) and infants (154) whose mothers developed symptomatic and confirmed Zika infection during pregnancy | 7 | Mother: 170/170 | 7.6 mo ± 4.3 (mean ± SD) | ABR – 6/68 (8.8%) |
| Total | 962 | 482 | Children: 145/245 (PCR or IgM in CSF or blood or urine) | Any informed auditory evaluation – 624 |
d, days; mo, months; wks, weeks; CSF, Cerebrospinal Fluid; Aabr, automated Auditory Brainstem Response; NI, Not Informed; CP, Cephalic Perimeter; ND, Not Determined; IgM, Immunoglobulin M; PCR, Polymerase Chain Reaction; PRNT, Plaque Reduction Neutralization Test; T-OAE, Transient Otoacoustic Emissions; DP-OAE, Distortion Product Otoacoustic Emissions; ABR, Auditory Brainstem Response; FS-ABR, Frequency Specific Auditory Brainstem Response; HINE, Hammersmith Infant Neurologic Exam; CZS, Congenital Zika Syndrome; RE, Right Ear; LE, Left Ear.
This case is included in the case series of the same author. However other hearing tests were performed in the follow-up of this case. This child was removed from the counting of the total number of children in the studies, since it is duplicated.
This child with altered hearing test was microcephalic.
Only one of the children with altered hearing test was microcephalic.
4 of the 19 cases had normal CP at reassessment (probable misclassification at birth).
The median cephalic perimeter at birth was 29.4 cm (SD = 2.34).
Including 259 children in which the type of the stimulus in the ABR was not specified (probably a-ABR).
Absolute and relative frequency of children with altered hearing tests, overall and according to the presence of microcephaly.
| Hearing evaluation | Studies | Altered tests/tests performed | Microcephalic/altered tests | Altered microcephalic/tests microcephalic |
|---|---|---|---|---|
| T-OAE or DP-OAE | Borja et al. (2017) | 45/244 (18.4) | 35/45 (77.8) | 35/140 (25) |
| First a-ABR | Borja et al. (2017) | 68/448 | NA/68 | NA/NA |
| ABR (Neurodiagnostic-click) | Marques Abramov et al. (2018) | 3/19 (15.8) | 3/19 (15.8) | 3/19 (15.8) |
| FS-ABR | Leal et al. (2016) | 5/19 | 5/5 (100) | 5/19 (26.3) |
| Behavioral Audiometry | Leal et al. (2016) | 1/1 (100) | 1/1 (100) | 1/1 (100) |
| Other hearing evaluations | Satterfield-Nash et al. (2017) | 14/20 | 14/14 (100) | 14/20 |
a-ABR, automated Auditory Brainstem Response; T-OAE, Transient Otoacoustic Emissions; DP-OAE, Distortion Product Otoacoustic Emissions; ABR, Auditory Brainstem Response; FS-ABR, Frequency Specific Auditory Brainstem Response.
5 patients with sensorineural hearing loss and severe microcephaly (1 patient duplicated in the 2 studies of Leal et al., 2016 – removed from numerator and denominator).
The study of Besnard et al. does not specify how many children were tested with hearing tests; only reports that one of them had altered test.
19 patients were submitted to HINE (Hammersmith Infant Neurologic Exam) – response to auditory stimuli with rattle or bell – and one child had the hearing test not specified.
Considerations on the pathogenesis of auditory impairment according to different authors.
| Author (year); country | Hypothesis about the pathogenesis |
|---|---|
| Martins et al. (2017); Brazil | “Hearing compatible with normal cochlear function presenting with neural synchrony changes can be classified as a neuropathy. As such, it is verified that this definition is compatible with the characteristics observed in both cases in this study”. “In view of all the information quoted and analyzed, it is suggested that ZIKV can damage auditory nerve pathways and, in that way, impair communication in adult patients”. |
| Vinhaes et al. (2017); Brazil | “The mechanism of SNHL associated with acute virus infection involves damage of the inner ear or auditory nerve, by a direct viral effect or mediated by an autoimmune process as previously described”. |
| Leal et al. (2016); Brazil | “In the majority of cases of hearing loss associated with congenital viral infection, the damage to the auditory system is within the cochlea. It is likely that similar lesions account for the hearing deficit in children with congenital Zika virus infection, although histologic studies are needed to confirm this. However, a concomitant central origin cannot be discounted, and behavioral auditory evaluation might provide additional information”. |
| Leal et al. (2016); Brazil | “It is still uncertain if the tissue damages caused by the intrauterine ZIKV infection are an expression of a direct effect of the virus itself or of an immune reaction from the host. Further histologic studies are necessary to determine the exact pathogenesis of the disease”. |
| Borja et al. (2017); Brazil | “In this study, earlier absolute latencies were observed in children with microcephaly, with high-intensity stimuli for the investigation of the neurophysiological integrity of the brainstem. Considering the affinity of ZIKV for nerve tissue, it is possible that the neuroconduction of the acoustic stimulus in children exposed to the virus and with microcephaly is different from that of other children, even those exposed to other congenital infections. It is plausible to assume that the norms available in studies validated and used for the purpose of audiological diagnosis in term and preterm neonates do not apply to this population”. |
| “… it should be considered that the neurological changes found in the imaging examinations imply the possibility of late hearing loss, cognitive and language alterations. Cognitive development is intrinsically linked to satisfactory relationships between sensory, perceptive, motor, linguistic, intellectual and psychological functions.” | |
| Marques Abramov et al. (2018); Brazil | “Our results about brainstem functional normality are challenging, considering the substantial disruption of brain development as well as evidence suggesting the action of ZV on progenitor cells, from the cell proliferation phase. Although the brainstem develops in parallel with the telencephalon in the early stages of embryogenesis, the development of the brainstem does not exhibit the same neuronal migration processes observed in the telencephalon, suggesting that the ZV primarily acts on specific mechanisms of cerebral cortex formation extending from the first to the third trimester.” |
| “The functional organization of the brainstem, as observed in this study, indicates an adequate centripetal development process in children with microcephaly, with a neuronal and synaptic organization comparable to typical development, restricting the disorder produced by the ZV to more specific processes of CNS development, probably limited to the telencephalon.” | |
| “The increase of the deviation of the normality of latencies of wave I with the age at the time of examination suggests that the ZV infection leads to a progressive process in peripheral auditory nerve or sensorineural structures.” | |
| Mittal et al. (2017); USA | “Many infants with microcephaly exhibit SNHL without clear injury to the inner ear structures, possibly representing auditory impairment at the brainstem or cortical level. Another possibility could be inflammatory changes within the cochlea because the virus may have direct access to these structures via the cochlear aqueduct. But because of the association with microcephaly, some might question whether the HL in infants with ZIKV infection is central in origin due to brain malformation, rather than abnormality at the cochlear level”. |
| “In summary, ZIKV exposure is associated with HL in infants and adults. Hearing loss can occur as a result of the damage to the inner ear or auditory nerve, by a direct viral effect or mediated by an autoimmune process as demonstrated in the case of other viral infections.” | |
| Racicot et al. (2017); USA | “Mutations affecting Diaph expression (Diaph 1 and 3) can cause microcephaly and hearing loss in humans and mice.” |
| “Neurotropic viruses can significantly affect NPC (neuroprogenitor cell) functions, including cell fate decisions, proliferation, migration and survival.” | |
| “Most viruses express gene products that can functionally ‘hijack’ the Rho-Diaph system, sequestering these proteins for the purpose of modifying the actin cytoskeleton to promote viral entry, assembly and spread.” | |
| “We hypothesize that viral ‘repurposing’ of Diaphs disrupts normal host cellular functions, resulting in premature NPC differentiation or apoptosis, as mentioned previously. If viruses sequester Diaphs in NPCs, preventing them from executing their normal cellular functions, it follows that neurological phenotypes associated with these infections would be similar to those caused by genetic mutations of Diaphs.” | |
| Leal et al. (2019); Brazil | “In all studies, it seems clear that the auditory impairment is closely related to the presence of microcephaly and its severity.” |
| “An issue not yet clarified is the topography of the lesion responsible for hearing loss produced by ZikV infection. None of these children had any anatomical abnormalities of the inner ear on imaging examinations, but it is well known that other congenital infections can cause deafness without any cochlear malformation; therefore, it is not possible to rule out a sensory impairment in these cases.” | |
| “…severe changes in the central nervous system of many of these newborns are a possible origin of the auditory impairment, as already demonstrated in other conditions that involve the auditory pathways.” | |
| “We are far from understanding if the lesions are produced directly by the virus itself or a result of an inflammatory tissue reaction. To date, no study has been addressed regarding a histologic analysis of the auditory sensory or neural structures.” |
Recommendations on hearing screening and follow up for patients with congenital or acquired Zika virus infection.
| Author, year, journal | Document title and publication type | Recommendations |
|---|---|---|
| Adebanjo et al., 2017 | Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with possible Congenital Zika Virus Infection – United States, October, 2017. Guideline article | Infants with clinical findings consistent with CZS or Infants without CZS who were born to mothers with laboratory evidence of possible maternal Zika virus infection during pregnancy aABR by age 1 month if the newborn hearing screen was passed using only OAE. |
| Amendment to the previous recommendations of 2016: A diagnostic ABR at 4–6 months or behavioral audiology at age 9 months is no longer recommended if the initial hearing screen is passed by automated ABR because of absence of data suggesting delayed-onset hearing loss in congenital ZIKV infection. | ||
| Russell et al., 2016 | Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with possible Congenital Zika Virus Infection – United States, August 2016. Guideline article | Mothers with laboratory evidence of ZIKV with infants with no evidence of clinical abnormalities: |
| Mothers with laboratory evidence of ZIKV, with infants with abnormalities consistent with CZS: | ||
| Mothers not tested for ZIKV or tested outside of appropriate Window | ||
| Mothers not tested for ZIKV or tested outside of appropriate Window | ||
| Brasil. Ministério da Saúde. Scretaria de Atenção à Saúde, 2015. | Protocol for Health Care and Response to the Occurrence of Microcephaly related to Zika virus Infection. Manual of Health Care | Newborn with microcephaly: Hearing screening test (OAE) with 24–48 h of life and ABR ideally in the maternity. If there is no equipment for ABR, send the patient to the nearest referral service (Specialized Center for Rehabilitation with hearing modality or High Complexity Auditory Rehabilitation Center), until the first month of life. In case of failure, retest must be performed within 30 days, preferably at the same place as the previous test. In case of retest failure, the child should be immediately referred for otorhinolaryngological and audiological diagnostic evaluation. Neonatal hearing screening test should not be performed in children with ear malformations (even if unilateral). These patients should be sent directly to a referral service for otorhinolaryngological and audiological diagnosis, according to the Neonatal Hearing Screening Guidelines. If hearing loss is diagnosed, the child should be sent for rehabilitation in reference service in auditory rehabilitation: Specialized Center in Rehabilitation with hearing modality or High Complexity. Auditory Rehabilitation Center. Microcephaly is a risk indicator for hearing loss. |
| Leal et al., 2016 | Hearing Loss in Infants with Microcephaly and Evidence of Congenital Zika Virus Infection – Brazil, November 2015–May 2016. Case series | To elucidate the full spectrum of hearing loss in infants with congenital Zika virus infection, testing and follow-up of all children born to women who had Zika virus infection during pregnancy, including infants with no apparent anomalies at birth, is needed. |
| Sensorineural hearing loss should be considered part of the spectrum of clinical findings associated with congenital Zika virus infection, and congenital Zika virus infection should be considered a risk factor for hearing loss in auditory screening programs. | ||
| Children with evidence of congenital Zika virus infection who have normal initial screening tests should receive regular follow-up, because onset of hearing loss could be delayed and the loss could be progressive. | ||
| Leal et al., 2016 | Sensorineural hearing loss in a case of congenital Zika virus. Case report | In hearing assessments protocols for neonates, mother's infection by Zika virus should be included among the risk factors for hearing loss. |
| Borja et al., 2017 | Hearing screening in children exposed to Zika virus during pregnancy. Case series | The health services that provide care to this population (children exposed to Zika virus during pregnancy) should make parents or caregivers aware of the need to continue monitoring of hearing development up to 24 months of age, even if the child has passed the screening tests, understanding that late hearing loss may occur, as well as auditory development may present important delays that may compromise the development of language. |
| Satterfield-Nash et al., 2017 | Health and Development at Age 19–24 Months of 19 Children Who Were Born with Microcephaly and Laboratory Evidence of Congenital Zika Virus Infection During the 2015 Zika Virus Outbreak – Brazil, 2017. Case series | These findings allow for anticipation of medical and social service needs of affected children and their families, including early intervention services, and planning for resources to support these families in health care and community settings in Brazil, the United States, and other countries. |
| Children with disabilities related to congenital Zika virus infection will need multidisciplinary care from various pediatric subspecialists (10). | ||
| Long-term follow-up and measurement of developmental progression of children affected by Zika virus can inform intervention services and sub-specialties needed to provide optimal care for these children. | ||
| Silva et al., 2017. | Hearing screening in children exposed to zika virus. Case series | It is recommended that infants with microcephaly, exposed to the Zika virus, be screened with a-BAEP, since exposure to the Zika virus has been described as a risk indicator for hearing loss (RIHL) (Ministry of Health, 2016). The justification for performing this test in children with RIHL is the higher prevalence of non-identifiable retrocochlear hearing loss through otoacoustic emissions (MINISTRY OF HEALTH, 2012). |
| Mittal et al., 2017 | A Possible Association Between Hearing Loss and Zika Virus Infection. Opinion article | Otolaryngologists should monitor ZIKV exposed infants without hearing impairment at birth because they may develop HL at later stages of life. |
| The early diagnosis and detection of HL in ZIKV-exposed infants will improve auditory rehabilitation, leading to improved long-term developmental outcomes. | ||
| Fandiño-Cárdenas et al., 2018 | Zika Virus Infection during Pregnancy and Sensorineural Hearing Loss among Children at 3 and 24 Months Post-Partum. Case series | Hearing loss because of congenital ZIKV can be sensorineural, neural, conductive, alone or mixed. Therefore, a complete hearing assessment, including aABR and DPOAE, should be performed on all ZIKA-infected patients, thus ruling out auditory neuropathy syndrome and sensorineural hearing loss. |
| Regardless if microcephaly is present, every neonate born with suspicious of gestational or congenital Zika infection needs to be tested at birth and in a follow-up with a complete audiology assessment, given the potential impairment of hearing over time, as occurs in CMV. | ||
| The nature of the hearing loss in ZIKV infection may be progressive, and a follow-up hearing test must be conducted at least during the first 5 years o life. | ||
| Martins et al., 2017 | Otological findings in patients following infection with Zika virus: case report. Case series | In view of the rapid spread of ZIKV in Brazil, it is suggested that patients should monitor their auditory health following ZIKV infection, since even though those patients may not report any alterations in their hearing accuracy; it is possible that the central auditory system could be affected. |
| Vinhaes et al., 2017 | Transient Hearing Loss in Adults Associated With Zika Virus Infection. Case series | Further investigation might also highlight other possible rare events such as permanent hearing loss, facilitating the possible recommendation of audiometry examinations in adults during ZIKV outbreaks. |
| Peloggia et al., 2018 | Zika virus exposure in pregnancy and its association with newborn visual anomalies and hearing loss. Narrative review | Hearing examination of infants with suspected CZS infection, even in the absence of microcephaly, is essential, because the associated impairments might be underestimated if microcephaly continues to be the only inclusion criterion during the screening of this group of infants. |
| Leite et al., 2018 | Hearing Screening in children with Congenital Zika Virus Syndrome in Fortaleza, Ceará, Brazil, 2016. Case series | The inclusion of the tympanometry in the hearing screening before the referral to the ABR is suggested. |
| The hearing screening should be performed in children with CZS right after birth and the referral to the clinical and audiological diagnosis occur only in those who fail the screening, in early age. | ||
| The a-ABR should be included in the hearing screening recommendation for children with CZS. | ||
| Lage et al., 2019 | Clinical, Neuroimaging, and Neurophysiological Findings in Children with Microcephaly Related to Congenital Zika Virus Infection. Case series | Children with microcephaly related to CZS need regular follow-ups, even the ones with normal initial screening tests, because hearing loss, like in other congenital viral infections, can be delayed and progressive. |
| Leal et al., 2019 | Hearing Loss From Congenital Zika Virus Infection. Narrative Review | As congenital ZIKV infection should be considered a risk factor for hearing loss, neonatal hearing screening with auditory-evoked potential is recommended, maintaining clinical follow-up, even for those who pass the screening, with at least 1 audiological evaluation in the period between 24 and 30 months of age, as recommended for children who present risk factors for hearing loss. |
| Calle-Giraldo et al., 2019 | Outcomes of Congenital Zika Virus Infection During an Outbreak in Valle del Cauca, Colombia. Case series | Infants exposed during pregnancy should receive close neurologic, ophthalmologic and audiologic monitoring, even in the absence of microcephaly. |
a-ABR, automated Auditory Brainstem Response; CZS, Congenital Zika Virus Syndrome; HC, Head (occipitofrontal) Circumference; OAE, Otoacoustic Emissions; PE, Physical Exam; ZIKV, Zika Virus.
Mothers should be tested by rRT-PCR within 2 weeks of exposure or symptom onset, or by IgM within 2–12 weeks of exposure or symptom onset. Because of the decline in IgM antibody titers and viral RNA levels over time, negative maternal testing 12 weeks after exposure does not rule out maternal infection.
Sub-sample from Zodiac (Zika Outcomes and Development in Infants and Children) case–control study.
Presented at the II Brazilian Congress of Health Sciences.
| Database | Search strategy | Results ( |
|---|---|---|
| PUBMED | (((Zika[Title/Abstract] OR ZIKV[Title/Abstract]))) AND ((Acoustic OR Audiometry OR Tympanometry OR Auditory OR “Evoked Potentials” OR Psychoacoustics OR “Evoked Response” OR P300 OR ABR OR BERA) OR (Hearing OR Hypoacusis OR Deafness OR Audition OR Dysacusis OR cochlear OR retrocochlear)) | 32 |
| SCOPUS | (TITLE-ABS-KEY (zika OR zikv)) AND ((TITLE-ASB-KEY (acoustic OR audiometry OR tympanometry OR auditory OR “Evoked Potentials” OR psychoacoustics OR “Evoked Response” OR p300 OR abr OR bera)) OR (TITLE-ABS-KEY (hearing OR hypoacusis OR deafness OR audition OR dysacusis OR cochlear OR retrocochlear))) | 58 |
| SCIELO | (Zika OR ZIKV) AND (Acoustic OR Audiometry OR Tympanometry OR Auditory OR “Evoked Potentials” OR Psychoacoustics OR “Evoked Response” OR P300 OR ABR OR BERA OR Hearing OR Hypoacusis OR Deafness OR Audition OR Dysacusis OR cochlear OR retrocochlear) | 15 |
| LILACS | (Zika OR ZIKV) AND (Acoustic OR Audiometry OR Tympanometry OR Auditory OR “Evoked Potentials” OR Psychoacoustics OR “Evoked Response” OR P300 OR ABR OR BERA OR Hearing OR Hypoacusis OR Deafness OR Audition OR Dysacusis OR cochlear OR retrocochlear) | 21 |
| Web of Science | (TITLE-ABS-KEY (zika OR zikv)) AND ((TITLE-ASB-KEY (acoustic OR audiometry OR tympanometry OR auditory OR “Evoked Potentials” OR psychoacoustics OR “Evoked Response” OR p300 OR abr OR bera)) OR (TITLE-ABS-KEY (hearing OR hypoacusis OR deafness OR audition OR dysacusis OR cochlear OR retrocochlear))) | 33 |
| GOOGLE/GOOGLE Scholar | Zika AND hearing | 5 |
| Title | 1 | The words “case report” (or “case study”) should be in the title along with phenomenon of greatest interest (e.g., symptom, diagnosis, test, intervention) |
| Keywords | 2 | The key elements of this case in 2–5 words. |
| Abstract | 3a | a) Introduction – What does this case add? |
| 3b | b) Case presentation: The main symptoms of the patient; The main clinical findings; The main diagnoses and interventions; The main outcomes | |
| 3c | c) Conclusion – What were the main “take-away” lessons from this case? | |
| Introduction | 4 | Brief background summary of the case referencing the relevant medical literature. |
| Patient information | 5a | Demographic information of the patient (age, gender, ethnicity, occupation) |
| 5b | Main symptoms of the patient (his or her chief complaints) | |
| 5c | Medical, family, and psychosocial history including diet, lifestyle, and genetic information whenever possible and details about relevant comorbidities and past interventions and their outcomes | |
| Clinical findings | 6 | Describe the relevant Physical Examination (PE) findings |
| Timeline | 7 | Depict important dates and times in the case (Table or Figure) |
| Diagnostic assessment | 8a | Diagnostic methods (e.g., PE, laboratory testing, imaging, questionnaires) |
| 8b | Diagnostic challenges (e.g., financial, language/cultural) | |
| 8c | Diagnostic reasoning including other diagnoses considered | |
| 8d | Prognostic characteristics (e.g., staging) where applicable | |
| Therapeutic interventions | 9a | Types of intervention (e.g., pharmacologic, surgical, preventive, self-care) |
| 9b | Administration (e.g., dosage, strength, duration) | |
| 9c | Changes in intervention (with rationale) | |
| Follow-up and outcomes | 10a | Clinician and patient-assessed outcomes |
| 10b | Important follow-up test results (positive or negative) | |
| 10c | Intervention adherence and tolerability (and how this was assessed) | |
| 10d | Adverse and unanticipated events | |
| Discussion | 11a | Strengths and limitations of the management of this case |
| 11b | Relevant medical literature | |
| 11c | Rationale for conclusions (including assessments of cause and effect) | |
| 11d | Main “take-away” lessons of this case report | |
| Patient perspective | 12 | The patient should share their perspective or experience whenever possible |
| Informed consent | 13 | Did the patient give informed consent? Please provide if requested |
| Title | 1 | Are words related to the main issue (hearing) in the title? |
| Keywords | 2 | 2 to 5 keywords to identify areas of interest in the case report |
| Abstract | 3a | Introduction – One statement contextualizing and justifying the study theme? |
| 3b | Does the abstract present objectives, methods, results and conclusions? | |
| Introduction | 4 | One or two paragraphs contextualizing and justifying the theme referencing the relevant medical literature |
| Objectives | 5 | Was the study question or objective clearly stated? |
| Participants | 6a | Was the study population clearly specified and defined? |
| 6b | Was a sample size justification, power description, or variance and effect estimates provided? | |
| 6c | Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | |
| 6d | Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? | |
| 6e | Were the cases clearly defined and differentiated from controls? | |
| 6f | If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | |
| 6g | Was there use of concurrent controls? | |
| Evaluation of exposure | 7a | Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? |
| 7b | Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | |
| 7c | Were the assessors of exposure/risk blinded to the case or control status of participants? | |
| Results | 10a | Were the results well-described? (Does it present adequate descriptive statistics?) |
| 10b | Were there comparisons between subgroups, association measures with adequate statistics (precision measures)? | |
| 10c | Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | |
| Discussion | 11a | Strengths and limitations of the management of this case |
| 11b | Discussion of relevant medical literature | |
| 11c | Rationale for conclusions (including assessments of cause and effect) | |
| Conclusion | 12 | What were the main “take-away” lessons from this case? |
| Informed consent | 13 | Did the patient give informed consent? |